Integrated Safety Analysis of Abrocitinib in 635 Adolescent Patients With Moderate-To-Severe Atopic Dermatitis With Over 1000 Patient-Years of Exposure. J of Skin 2024, 8 (2), s379. https://doi.org/10.25251/skin.8.supp.379.